Pre-clinical assessments for precision medicine in myeloma - OASIS
Research type
Research Study
Full title
Optimised pre-clinical Assessment of Suitable Investigational agents for preciSion medicine in myeloma - OASIS
IRAS ID
209666
Contact name
Chloe Burrows
Contact email
Sponsor organisation
The Institute of Cancer Research
Duration of Study in the UK
9 years, 0 months, 1 days
Research summary
OASIS is a multi-centre tissue and data collection study for patients with symptomatic multiple myeloma that ultimately aims at identifying novel future therapies for patients with an unmet clinical need. The patient blood and bone marrow material collected in the study is used for laboratory cell culture drug testing to pre-clinically identify the most promising drug candidates for future clinical development. Patient material will also be tested to identify molecular features, e.g. gene mutations, of the tumour that could predict response to a specific therapy. This could speed up a future clinical development plan in the sense of tailored, stratified therapy. Outcome data of participants will be collected and also correlated with molecular features of the tumour to identify groups of patients that have an unmet clinical need when treated with standard therapies on the NHS. These groups will be prioritised for the future molecularly stratified clinical drug development programs. Patients may be informed about results of the molecular tumour testing if it may open therapeutic options for them, e.g. a molecularly targeted clinical trial for tumours with a specific mutation. A sub-group of 100 patients will also have blood samples taken for cfDNA following 6 cycles of induction therapy/ASCT for evaluation of novel testing strategies.
REC name
London - Chelsea Research Ethics Committee
REC reference
19/LO/0599
Date of REC Opinion
23 May 2019
REC opinion
Favourable Opinion